Company data
Spyre Therapeutics, Inc. employees and revenue per employee
SYRE · Biotechnology · $9.25B market cap
Spyre Therapeutics, Inc. had 30 employees at the end of fiscal Dec 2023, down 56.5% from a year earlier. Revenue for the year was $886,000, down 62.0% from a year earlier, or $30K per employee. Revenue fell, and headcount fell or held flat with it.
The latest annual report we hold is more than two years old, so these numbers may be out of date.
Employees
30
-56.5% YoY
Revenue
$886,000
-62.0% YoY
Revenue / employee
$30K
Peer median $574K
Rank in industry
39 of 40
Biotechnology
Open roles
7
233 per 1,000 staff
Headcount against revenue
Both lines start at 100 in the first year we hold, so you can see which one grew faster.
Hover a year for the numbers.
| Year ending | Employees | Revenue | Per employee | Staff YoY | Revenue YoY |
|---|---|---|---|---|---|
| Dec 2023 | 30 | $886,000 | $30K | -56.5% | -62.0% |
| Dec 2022 | 69 | $2.3M | $34K | -31.7% | -87.6% |
| Dec 2021 | 101 | $18.7M | $186K | — | — |
| Dec 2018 | 61 | $3.9M | $64K | +41.9% | -25.3% |
| Dec 2017 | 43 | $5.2M | $121K | +43.3% | +12.5% |
| Dec 2016 | 30 | $4.6M | $154K | — | — |
Open roles on its job board: 7 (233 per 1,000 staff, against its latest annual headcount), as of 2026-10-07. Tracked since 2026-10-03. No 90 day change yet.
Spyre Therapeutics, Inc. against similar companies
The closest industry peers by revenue, from Biotechnology.
| Company | Employees | Revenue | Revenue / employee | Shape |
|---|---|---|---|---|
| PTGX Protagonist Therapeutics, Inc. | 132 | $46.0M | $349K | Hiring into decline |
| NUVB Nuvation Bio Inc. | 298 | $62.9M | $211K | Efficient growth |
| KYMR Kymera Therapeutics, Inc. | 238 | $39.2M | $165K | Hiring into decline |
| RLAY Relay Therapeutics, Inc. | 192 | $15.4M | $80K | Leaner |
| PRAX Praxis Precision Medicines, Inc. | 116 | $8.6M | $74K | Efficient growth |
| PGEN Precigen, Inc. | 160 | $9.7M | $61K | Efficient growth |
| IMNM Immunome, Inc. | 177 | $6.9M | $39K | Hiring into decline |
| SYRE Spyre Therapeutics, Inc. | 30 | $886,000 | $30K | Contracting |
| CRNX Crinetics Pharmaceuticals, Inc. | 594 | $7.7M | $13K | Efficient growth |
Questions about Spyre Therapeutics, Inc.
- How many employees does Spyre Therapeutics, Inc. have?
- Spyre Therapeutics, Inc. reported 30 employees for the fiscal year ending Dec 2023, in the annual report it filed on February 29, 2024. That is down 56.5% from a year earlier.
- What is Spyre Therapeutics, Inc.'s revenue per employee?
- Spyre Therapeutics, Inc. brought in $886,000 of revenue in fiscal Dec 2023, which is $30K per employee. That ranks 39 of 40 companies we track in Biotechnology, where the median is $574K.
- Is Spyre Therapeutics, Inc. hiring?
- Spyre Therapeutics, Inc.'s public job board listed 7 open roles on October 7, 2026, about 233 per 1,000 staff.
- Where do these numbers come from?
- Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.
Free game
Think you can pick better than the S&P 500?
Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.
Enter the challengeMore data
Compare SYRE with the rest of the market
See who earns the most per employee, who is hiring, and who is cutting, across every company we track.
Source: employee counts and revenue as stated in Spyre Therapeutics, Inc.'s annual reports (Form 10-K), latest filed February 29, 2024. This is data, not a recommendation to buy or sell SYRE.